Basic Information




Gene symbol tk


GTO ID GTC1687
Trial ID NCT03029871
Disease Lung Non-Small Cell Carcinoma
Altered gene E1|E3|yCD|tk|ADP
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment AdV5-yCD/mutTKSR39rep-AdVP
PhasePhase1
Recruitment statusWithdrawn
TitlePhase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic Gene Therapy in Combination With Stereotactic Body Radiation Therapy (SBRT) in Clinical Stage 1/11A (T1A-T2B) Non-Small Cell Lung Cancer
Year2007
CountryUnited States
Company sponsorHenry Ford Health System
Other ID(s)10835
Vector information
Vectoradenovirus
ConstructAd5-yCD/mutTKSR39rep-ADP
Vector typeadenoviral serotype 5 (Ad5) vector
Transgene/Inserted geneyCD; HSV-TK; ADP
Regulatory elementhuman cytomegalovirus (CMV) promoter
Viral genome modificationAd5-yCD/mutTKSR39rep-ADP contains a yeast cytosine deaminase (yCD)/mutantSR39 herpes simplex virus thymidine kinase (mutTKSR39) fusion gene in the E1 region as well as the Ad5 adenoviral death protein (ADP) gene in the E3 region.

Clinical Result

Cohort1: dose level 1
Administration route intratumoral injection
Dosage 1E11 vp
Age Adult, Older_Adult
Cohort2: dose level 2
Administration route intratumoral injection
Dosage 3E11 vp
Age Adult, Older_Adult
Cohort3: dose level 3
Administration route intratumoral injection
Dosage 1E12 vp
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph